Single-chain antibody fragment-based adsorbent for the extracorporeal removal of b 2 -microglobulin.
A frequent complication of end-stage renal disease (ESRD) is dialysis-related amyloidosis (DRA), a debilitating disorder associated with the long-term accumulation of b 2 -microglobulin (b 2 -m) [1, 2] . Symptoms are caused by the formation of amyloid deposits and include chronic pain, carpal tunnel syndrome, nerve compressions, and cystic bone lesions with associated fractures. b 2 -m, the primary constituent of DRA amyloid, is a highly conserved globular protein (11.8 kD) that is secreted by all nucleated cells and is specifically removed from the blood plasma by healthy kidneys. Conventional kidney function replacement technologies such as hemodialysis, hemodiafiltration, and peritoneal dialysis are believed to remove insufficient quantities of b 2 -m, as they are nonspecific and based on size exclusion [3] . Even so, research has revealed a correlation between the removal of b 2 -m from the circulation and a delay in the occurrence of symptoms [2, 4, 5] . In recent years, adsorbent matrices that are based on hydrophobic interaction and size exclusion (Lixelle ; Kaneka Co., Ltd., Tokyo, Japan and Betasorb ; Renaltech International LLC, New York, NY, USA) have been developed for the extracorporeal removal of b 2 -m [6, 7] . However, their specificity and/or affinity for b 2 -m remains in question, complicating the evaluation of patient outcome due to their use [8] [9] [10] .
The ideal technology for the extracorporeal removal of b 2 -m should be highly specific, so as to prevent the significant loss of proteins and other molecules that are beneficial to the patient. A highly specific b 2 -m removal system could also serve as a valuable tool for research. It could potentially be used to study the therapeutic efficacy of b 2 -m clearance independent of the removal of other molecules that have also been implicated in the pathogenesis of DRA, such as inflammatory cytokines [11] [12] [13] . The ideal extracorporeal b 2 -m removal system should also possess an affinity for b 2 -m that is strong enough to bring the concentration to a level that is well below normal (1 mg/mL) [14] . This high affinity will serve to maintain a fast apparent rate of adsorption during the available treatment time-period (by maximizing the concentration gradient driving the rate of mass transfer). Antibodies are a logical choice as the active species for a b 2 -m removal strategy, as they can be highly specific and posses a high affinity for their target molecules.
We hypothesize that b 2 -m can be efficiently removed from the circulation by immunoadsorptive particles contained within a novel, multicompartment extracorporeal device [the Vortex Flow Plasmapheretic Reactor (VFPR)]. Experiments previously conducted in vitro with a model immunoadsorbent (BBM.1 monoclonal antibodies [15] immobilized onto agarose gel beads), a VFPR device prototype, and whole human blood support the feasibility of the approach [16] . Several characteristics of the whole BBM.1 antibody-based immunoadsorbent were found to be quite promising, including its high binding affinity for b 2 -m (K D = 0.1 ± 0.1 mg/L) as well as its ability to be regenerated repeatedly. However, for the proposed therapy to be successful, a new immunoadsorbent with a dramatically increased b 2 -m adsorption site density needs to be developed.
As immunoadsorption ligands, single-chain variable region antibody fragments (scFv) (Fig. 1 ) offer several potential advantages over whole, hybridoma-produced monoclonal antibodies. The transfer of antibody genes to a nonhybridoma expression vector provides the opportunity to eliminate the production of unwanted immunoglobulins that may be secreted by the hybridoma (which has been suspected to be the case for BBM.1) [16] . ScFv fragments are also smaller in size, which should theoretically allow for higher densities of accessible adsorption sites (steric argument). The properties (stability, affinity, expression yield) of scFv fragments can be engineered through in vitro evolution in a yeast display format [17] [18] [19] . The fact that scFv fragments can be produced through microbial expression vectors provides greater flexibility for the optimization of the production process economics [20] . Furthermore, very high yields (3.1 g scFv/L culture) of properly folded scFv fragments have been expressed in and purified from the cytoplasm of Escherichia coli [21] . These potential advantages of scFv fragments, combined with the demonstrated affinity and regeneration capacity of the immobilized BBM.1 antibody, motivated the development of an immunoadsorbent that is based upon a BBM.1 scFv fragment.
METHODS

Labeling of b 2 -m
Recombinant human b 2 -m was prepared as previously described [16] and biotinylated using the FluoReporter Biotin-XX Protein Labeling Kit (Molecular Probes, Eugene, OR, USA). A 20 mg/mL working stock of biotin-XX (sulfosuccinimidyl ester, sodium salt) in dimethylsulfoxide (DMSO) was prepared and a tenfold molar excess was added to 1.6 mg/mL b 2 -m in phosphatebuffered saline (PBS), pH 7.4 (10 mmol/L PO 4 , 138 mmol/L NaCl, and 2.7 mmol/L KCl). The labeling reaction was performed at this pH to inhibit the reaction of the sulfosuccinimidyl ester with the primary amines of lysine residues, thereby favoring the labeling of the b 2 -m at the N-terminus. The reaction mixture was incubated on a rocker for 90 minutes at room temperature and subsequently dialyzed overnight into PBS 7.4 at 4
• C to remove any unreacted biotin-XX using a 6 to 8 kD membrane (Spectrum Laboratories, Rancho Dominguez, CA, USA). The final concentration of b 2 -m was determined using an extinction coefficient of 20,065 M −1 cm
at 280 nm as previously described [16] , while the degree of biotinylation (0.93 mol biotin/mol b 2 -m) was determined following the kit instructions. Recombinant human b 2 -m was labeled with Alexa Fluor 488 (carboxylic acid, succinimidyl ester), a fluorophore that is spectrally similar to fluorescein, but possesses greater brightness and photostability (Molecular Probes). The protocol used was essentially that described above for the biotinylation of b 2 -m. However, threefold molar excess of a 5 mg/mL working stock of labeling agent was added to 1.1 mg/mL of b 2 -m in PBS 7.4 for the labeling reaction. The final concentration and degree of labeling (0.056 mol fluorophore/mol b 2 -m) was determined using the extinction coefficient previously described [16] , and the protocol provided by Molecular Probes.
Cloning of V H and V L genes
The BBM.1 antibody-producing hybridoma cell line (HB-28) was purchased from ATCC (Manassas, VA, USA) and grown in T-flask static culture at 37
• C in a 5% CO 2 atmosphere. The growth media consisted of 90% The gene encoding the single-chain variable region antibody fragments (scFv) fragment of interest is cloned into the pCT302 plasmid (or derivative) in frame with the Aga2p mating protein, which is under control of the GAL1,10 promoter. The EBY100 strain of Saccharomyces cerevisiae possesses a single, integrated copy of the Aga1p gene, which is also under control of the GAL1,10 promoter. Upon induction by galactose, EBY100 cells transformed with pCT302 coexpress Aga1p and the Aga2p-scFv fusion. Aga1p is covalently bound to the cell wall and the Aga2p-scFv fusion. (B) Anti-HA tag antibody, anti-c-myc tag antibody and labeled antigen can be used to characterize the expression and activity of the scFv using a fluorescence-activated cell sorter (FACS). Objects are not drawn to scale.
RPMI 1640 medium (ATCC), 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 0.1 mg/mL streptomycin. The total RNA from 3 × 10 7 cells was isolated and reverse transcription-polymerase chain reaction (RT-PCR) was performed using the RNeasy Midi and the OneStep RT-PCR Kits from Qiagen (Valencia, CA, USA). Various combinations of the primers (0.5 lmol/L each) provided in the Mouse Ig-Primer Set (Novagen, Madison, WI, USA) were used along with 1 lg of RNA and 40 units of RNase inhibitor (Promega, Madison, WI, USA) in 50 lL RT-PCR reaction volumes. The thermocycler was run for one RT cycle of 30 minutes at 50
• C, one DNA polymerase-activation cycle of 15 minutes at 95
• C, 35 amplification cycles of 45 seconds at 94
• C, 1 minute at 60
• C, 1 minute at 72
• C, and 1 final extension cycle of 10 minutes at 72
• C. The PCR products were run on 1.2 or 2.0% agarose gels stained with ethidium bromide. Those displaying bands characteristic of V H and V L genes (about 500 base pairs in length) were purified using the QIAquick Kit (Qiagen) and ligated into the pSTBlue-1 plasmid (Novagen). The ligation products were used to transform NovaBlue Singles TM competent cells (included in the pSTBlue-1 Perfectly Blunt Cloning Kit from Novagen), which were plated onto Luria-Bertani (LB) medium agar plates containing 50 mg/mL ampicillin. After incubating the plates overnight at 37
• C, single colonies were each grown in 5 mL of LB containing 100-150 mg/L ampicillin at 37
• C overnight, and their plasmids were purified using the QIAprep Spin Miniprep Kit (Qiagen). The DNA inserts of the plasmid clones were sequenced and translated into peptide sequences so that they could be compared to the partial peptide sequences obtained through the N-terminal degradation of protein A-purified BBM.1 antibody.
Twenty-two cycles of N-terminal degradation were performed on a sample of whole BBM.1 antibody. For each degradation cycle, the two predominant residues were assigned to one of two peptide chains based on a match with the published sequence of the MOPC-21 myeloma j light chain [22] . This was done because the BBM.1 hybridoma cell line (HB-28) was created by fusing an anti-b 2 -m B cell with the X63-Ag8 myeloma [15] , a descendent of the MOPC-21 myeloma [23] . Both the X63-Ag8 and MOPC-21 myeloma cell lines have been shown to secrete the MOPC-21 j light chain as well as an IgG1 heavy chain [23] .
Display of scFv fragment by yeast
The V H and V L genes cloned from the BBM.1 hybridoma were initially expressed as a scFv fragment in a yeast display system [18] (Fig. 2) . This approach was selected because the b 2 -m binding affinity of the scFv could readily be characterized in a quantitative fashion and, if deemed necessary, would be in a vector that is amenable to in vitro evolution [24] .
Insert assembly. The scFv DNA insert was assembled in a V H -(Gly 4 Ser) 4 -V L configuration via the splicing by overlap extension (SOE) method [25] . All of the PCR reactions were performed using Cloned Pfu DNA polymerase and Cloned Pfu Reaction Buffer (Stratagene, La Jolla, CA, USA), following the manufacturer's instructions except where otherwise noted. During the first round of PCR, the V H and V L DNA inserts were amplified from the pSTBlue-1 plasmids (30 ng plasmid DNA in each 50 lL reaction volume) using the custom primers shown in Figure 3 (0.2 lmol/L each). The thermocycler was run for one cycle of 45 seconds at 98
• C, 28 cycles of 45 seconds at 98
• C, 90 seconds at 72
• C, and one cycle of 10 minutes at 72
• C. The resulting V H and V L PCR products were purified using the QIAquick Kit and quantitated by measuring their absorbance at 260 nm.
The second round of PCR was initiated without primers and was performed in a single 50 lL reaction volume with • C, 1 minute at 53
• C, 2 minutes at 72
• C. The 5 -V H and 3 -V L primers were then added (0.5 lmol/L each) and the thermocycler was run for 15 cycles of 1 minute at 96
• C, 1 minute at 53
• C. The resulting scFv DNA insert was purified and quantitated as above.
Plasmid construction. The purified scFv SOE PCR product and the pCTCON yeast display plasmid [26] (a derivative of the pCT302 plasmid [18] with a BamHI site added 5 to the c-myc sequence) were digested with BamHI and NheI restriction enzymes for more than 2 hours at 37
• C, according to the manufacturer's instructions (New England Biolabs, Beverly, MA, USA). The restriction digest products were purified using the QIAquick Kit, combined in an equimolar ratio (500 ng plasmid, 4 lg insert), and ligated using T4 DNA ligase (Stratagene) following the manufacturer's instructions. After incubating the ligation reaction mixture at room temperature for more than 2 hours, the reaction was heat deactivated at 65
• C for 10 minutes. The ligation products were used to transform XL1-Blue Supercompetent E. coli (Stratagene), following the manufacturer's protocol, and plated on LB agar plates containing 50 mg/mL ampicillin. Single colonies were each grown in 5 mL of LB containing 100 mg/L ampicillin at 37
• C overnight and their plasmid clones were purified using the QIAprep Spin Miniprep Kit. A plasmid clone with the desired in-frame scFv insert was identified through DNA sequencing and labeled pEAG1.
Yeast transformation, growth, and induction. EBY100 strain yeast cells [18] were transformed with pEAG1 through electroporation, plated onto SD-CAA agar plates ( 7 cells/mL [17] ) was centrifuged, resuspended in 5 mL of SG-CAA induction media (same as SD-CAA, but substituting galactose for dextrose), and incubated at 22
• C on an orbital shaker for approximately 20 hours.
Yeast labeling. The labeling of the yeast cells for fluorescence activated cell sorter (FACS) analysis was performed in a fashion similar to that previously described [27] . Each of a series of 1.5 mL centrifuge tubes were loaded with 1 × 10 6 EBY100 cells (transformed with pEAG1 and induced with galactose). The tubes were centrifuged and the yeast pellets were washed with 500 lL of PBS/bovine serum albumin (BSA) (PBS 7.4 with 0.1% BSA added as a carrier). Murine anti-HA tag antibody (12Ca5 Mab) (Roche, Basel, Switzerland) and biotinylated recombinant human b 2 -m were used as primary labeling agents at concentrations of 2 lg/mL and 1 × 10 −11 to 1 × 10 −6 mol/L, respectively. The primary labeling of each tube was carried out in 1.0 mL of PBS/BSA at room temperature on a rocker for 30 minutes. The cells were spun down and washed as above with ice-chilled PBS/BSA. Secondary labeling was conducted in 100 lL of PBS/BSA on ice for 15 minutes, using 40 lL/mL each of streptavidin-phycoerythrin (PE) (PharMingen, San Diego, CA, USA) and flourescein isothiocyanate (FITC)-conjugated ant-mouse IgG (Sigma Chemical Company, St. Louis, MO, USA). The cells were centrifuged at 4
• C and washed quickly with 500 lL of ice-chilled PBS/BSA. The labeled cell pellets were stored on ice and protected from light until FACS analysis.
Four additional yeast pellets were labeled for FACS analysis, which served as controls. The labeling was performed as described above, except that (1) the primary labels were omitted; (2) biotinylated recombinant human b 2 -m and streptavidin-PE were omitted; (3) the murine anti-HA tag antibody and FITC-conjugated antimouse IgG were omitted; and (4) unbiotinylated recombinant human b 2 -m was added in 100-fold molar excess to competitively inhibit the biotinylated b 2 -m.
FACS analysis. The labeled yeast cell pellets were each resuspended in approximately 1.0 mL of PBS/BSA and analyzed with an Epics XL FACS (Beckman Coulter, Fullerton, CA, USA) in a fashion similar to those previously described [17, 27] . Samples were gated by light scattering and then by FITC signal in order to avoid consideration of particles other than un-clustered scFvdisplaying yeast cells. The mean PE signal for more than 2 × 10 4 scFv-displaying cells labeled with each b 2 -m concentration was recorded. SPHERO TM Rainbow Calibration Particles (3.0 to 3.4 lm) (Spherotech, Libertyville, IL, USA) with six different known densities of surfaceimmobilized FITC were also analyzed (>1 × 10 3 counted at each density) to allow for the correlation of the mean FITC signal per cell to the mean number of scFv fragments displayed by each cell.
Mathematical modeling. Assuming a monovalent antibody-antigen binding interaction, the antibodyantigen equilibrium dissociation constant, K D , is defined in equation 1: 2 -m] eq can be expressed in terms of other variables as described in equations 2 and 3: 
where c 1 and c 2 are empirical constants. Equations 1 to 4 can be combined and rearranged to yield equation 5: 
Secretion of scFv fragment by yeast
A His6-tag and a cysteine residue were added to the C-terminus of the secreted version of the BBM.1 scFv fragment to facilitate its purification and subsequent immobilization. This location was chosen to minimize the interference of the purification tag and the immobilization bond with the b 2 -m binding site. It was deemed necessary to remove the Lys-Arg sequence near the C-terminus of the V L gene because it is known to be cleaved by the Kex2 protease within the trans-Golgi network of Saccharomyces cerevisiae [28, 29] .
Plasmid construction. The Lys-Arg sequence in the V L was removed by changing the Arg residue to Asn. This was achieved through PCR (50 lL reaction volume) with the 5 -V H and 3 -Lys-Asn primers ( Fig. 2 ) (0.25 lmol/L each) and the pEAG1 plasmid (1 lL). Cloned Pfu DNA polymerase and Cloned Pfu Reaction Buffer were used to carry out the reaction, following the manufacturer's instructions. The thermocycler was run for one cycle of 1 minute at 98
• C, 28 cycles of 1 minute at 98
• C. The resulting scFv PCR product was ligated into the pCT302 plasmid essentially as described for the construction of the pEAG1 plasmid, except that a 2:1 molar ratio of scFv insert to plasmid DNA was used during the ligation reaction. A plasmid clone with the desired scFv insert, pEAG2, was obtained from the ligation reaction products in the same manner as pEAG1.
The Kex2 protease resistant form of the BBM.1 scFv insert was amplified from the pEAG2 plasmid through PCR with the 5 -V H and 3 -His6-Cys primers (Fig. 3) . The PCR was performed as described for the creation of pEAG2, except that the thermocycler was run for one cycle of 1 minute at 98
• C, 1 minute at 55
• C. The resulting scFv insert was ligated into the secretion plasmid pRS-GALTwt [30] in frame with the synthetic pre pro signaling sequence [31] , under control of the GAL1,10 promoter. The ligation protocol was essentially that described for the construction of the pEAG1 from pCTCON, except that the BamHI restriction enzyme was replaced with XhoI (New England Biolabs) and a 4:1 molar ratio of scFv insert to plasmid DNA was used. A secretion plasmid clone with the desired scFv insert, pEAG3, was obtained from the ligation reaction products in the same manner as pEAG1 and pEAG2.
Yeast transformation, growth, and induction. YVH10 yeast, a protein disulfide isomerase overexpressing strain of Saccharomyces cerevisiae [32] , was transformed with pEAG3 and pRS314 (to add Trp resistance to allow selection on Trp-deficient media) [33] using the lithium acetate/single-stranded carrier DNA/polyethylene glycol method [34] . Cells were plated onto selective SD-SCAA plates [6.7 • C) for about 3 days (OD 600 = 17.4). The cell suspension was then centrifuged and the supernatant was 0.2 lm filtered and concentrated to an approximate volume of 400 mL using a 10 kD Prep/Scale-TFF TM -regenerated cellulose membrane (Millipore, Bedford, MA, USA).
Protein purification. The His6-tagged scFv fragment was purified from the concentrated cell culture supernatant via nickel affinity chromatography, for which PBS 8.0 (50 mol/L phosphate, 300 mmol/L sodium chloride) was used with varying imidazole concentrations. To remove metal contaminants, 5 mmol/L sodium ethylenediaminetetraacetic acid (EDTA) was added to the concentrated culture supernatant, which was placed in a 400 mL stirred ultrafiltration cell with a 10 kD YM10 regenerated cellulose disk membrane (Millipore). The cell was subsequently flushed with 2.8 L of PBS 8.0 to facilitate buffer exchange. To minimize the binding of untagged protein, 10 mmol/L imidazole was added and the protein was bound to a 5 mL column of Ni-NTA agarose gel beads (Qiagen). The resin was washed with 60 mL of 20 mmol/L imidazole and eluted with 30 mL of 250 mmol/L imidazole. The eluted protein was further purified by size-exclusion chromatography using Superose 12 prep grade resin (Amersham Biosciences, Uppsala, Sweden) eluted with PBS 7.4. The desired fractions were pooled and the concentration of scFv was measured by reading the absorbance at 280 nm, using a molar extinction coefficient of 51,130 L/mol cm −1 and a molecular weight of 29,032 g/mol. These values were calculated from the amino acid sequence and the formula reported by Pace et al [35] .
Immunoadsorbent based on scFv fragment
Protein immobilization. Immediately prior to immobilization, the purified scFv fragment was reduced with Immobilized TCEP (Tris[2-carboxyethyl] phosphine hydrochloride]) Disulfide Reducing Gel (Pierce, Rockford, IL, USA). The reaction was performed for 1 hour at room temperature on a rocker in 3.5 mL of PBS 7.2 (100 mmol/L PO 4 and 150 mmol/L NaCl) containing 15 mmol/L EDTA, 33% TCEP gel by volume, and 2.0 mg/mL scFv fragment. During the same hour, lysine Sepharose 4B (Amersham Biotech) was activated with sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (Sulfo-SMCC) (Pierce). Sulfo-SMCC is a heterobifunctional cross-linking agent that reacts with sulfhydryl and primary amine groups. This reaction was also performed for 1 hour at room temperature on a rocker, but in 4.5 mL of 150 mmol/L sodium bicarbonate buffer (pH 8.8) containing 1.8 mg/mL Sulfo-SMCC and 22% swollen lysine Sepharose 4B gel by volume.
Following the 1-hour incubation, the activated lysine gel was rinsed (several times, totaling 30 volumes) and resuspend with ice-cold PBS 7.2. Immediately thereafter, the reduced scFv fragment was removed from the TCEP gel by centrifuging it in a Micro BioSpin (BioRad, Hercules, CA, USA) column. The TCEP gel was rinsed with 1.0 mL of PBS 7.2 to improve the recovery of the scFv fragment. The scFv fragment immobilization reaction was performed for 24 hours on a rocker at 4
• C in 4.0 mL PBS 7.2 containing 4.4 mg scFv fragment and 0.45 mL Sulfo-SMCC activated gel (settled bed volume). The number free thiol groups per scFv fragment molecule, before and after contact with the TCEP gel, was measured using the Thiol and Sulfide Quantitation Kit obtained from Molecular Probes. The kit instructions were followed except that the degassing performed by argon bubbling instead of using vacuum desiccator.
The following day, the soluble scFv fragment was removed from the gel by centrifuging it in a Micro BioSpin column and the gel was rinsed four times with 2.0 mL of PBS 7.2. The gel was re-suspended in 2.0 mL PBS 7.2, containing 1 mmol/L L-cysteine as a quenching agent, and incubated overnight at 4
• C on a rocker. After quenching, the gel was centrifuged, rinsed four times as before, and resuspended in PBS 7.4. Equal volumes of the reduced scFv fragment, the quenching buffer, and the eight rinses were assayed for protein by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). A control matrix was prepared by immobilizing L-cysteine onto lysine Sepharose 4B gel following the above protocol, omitting the scFv-protein.
Characterization. Alexa Fluor 488-labeled recombinant human b 2 -m (b 2 m-AF488, see "Labeling of b 2 -m" section) was used to determine the b 2 -m adsorption capacity of the agarose-immobilized scFv antibody fragment and control matrix. A series of 0.5 mL centrifuge tubes were each loaded with 100 lL of 10% gel suspension in fetal calf serum (FCS)/PBS (75% FCS, 25% PBS 7.4, by volume), a saturating quantity of b 2 -m-AF488 (16, 12, or 10 lg; 0.96 mg/mL stock), and sufficient FCS/PBS to bring the total volume to 0.400 mL. The tubes were equilibrated at 37
• C for 1 hour on a rocker and then centrifuged. From each tube, three 100 lL volumes of supernatant were loaded into individual wells of a 96-well plate, which was also loaded with calibration standards (0, 10, 20, 30, 40, and 50 mg/L of b 2 -m-AF488 in FCS/PBS). The plate was read by a Mithras LB 940 plate reader (Berthold Technologies, Bad Wildbad, Germany), using excitation and emission wavelengths of 485 and 535 nm, respectively. A linear calibration curve was generated and was used to determine the b 2 -m-AF488 concentrations of the experimental samples. The b 2 m-adsorption capacity of the agarose-immobilized scFv antibody fragment was calculated from this data, using equation 6:
where q s is the adsorption site density (mg b 2 -m per mL of settled gel), V total is the total volume of each tube (mL), V gel is the settled-volume of the gel (lL), C 0 is the initial b 2 -m concentration (mg/L), and C eq is the concentration of desorbed b 2 -m at equilibrium (mg/L). For regeneration, the labeled gel was recovered from the centrifuge tubes, placed in a Micro Bio-Spin column, and centrifuged. The immunoadsorptive media was regenerated by rinsing it four times with 2.0 mL of stripping buffer (300 mmol/L glycine, pH 2.8). The regenerated media was rinsed four times with 2.0 mL of PBS 7.4, and then rinsed once and resuspended with FCS/PBS to make a 10% suspension. The adsorption capacity of the regenerated immunoadsorptive media was measured as above.
The affinity of the regenerated immunoadsorptive media for b 2 -m was assessed by following the protocol used to determine the adsorption capacity, except that each tube was loaded with twice the amount of gel along with a sub-saturating quantity of b 2 -m-AF488 (6 lg). The calibration standards also spanned a lower concentration range (0, 0.5, 1.0, 2.5, 5.0, 10, or 15 mg/mL).
Leaching of the scFv fragment by the stripping buffer was assayed through Western blotting. Diluting it with 13 mL of 100 mmol/L sodium phosphate, 1 mmol/L EDTA, pH 8.0, neutralized each 2.0 mL volume of stripping buffer. Equal volume samples of the neutralized stripping buffer and similarly diluted scFv from the immobilization reaction were run on SDS-PAGE with 5% 2-mercaptoethanol added to the sample buffer as a reducing agent. A polyvinylidene difluoride (PVDF) membrane was used for blotting, which was labeled with anti-His horseradish peroxidase (HRP) conjugate (using the included anti-His HRP conjugate blocking buffer) following the manufacturer's instructions (Qiagen). However, PBS 7.4 was used instead of Tris-buffered saline. Colorimetric detection was performed using the Opti-4CN TM Substrate Kit (BioRad), again following manufacturer's instructions.
The specificity of the scFv-based immunoadsorbent was evaluated via the immunoprecipitation of radiolabeled cell lysate obtained from a human white cell line. U373-MG astrocytoma cells were grown in Dulbecco's modified Eagle's medium (DMEM), supplemented with 5% FCS and 5% calf serum. Radiolabeling of cells was essentially performed as described in [36] . Briefly, cells were incubated in starvation medium (cysteine-and methionine-free DMEM supplemented with 5% FCS, 5% calf serum) for 1 hour at 37
• C at a density of 10 6 cells/ mL. Cells were then labeled for 3 hours at 10 6 cells per 100 lL of starvation medium containing 500 lCi of 
Statistical analysis
Measured quantities are reported as the mean ± the standard error of the mean (SEM), except for the scFv immobilization density and the mass ratio of adsorbed b 2 -m to immobilized antibody, for which the error estimates correspond to the accuracy of the gel volume measurement. The significance of the difference between two means was tested by analysis of variance (ANOVA) using a two-tailed P value of 0.05. Regressions were performed by minimizing the summed square error (SSE). 
RESULTS
Cloning of V H and V L genes
As resolved by agarose gel electrophoresis, one combination of the Ig-Prime Kit heavy chain primers [37] and were discarded. The sequences of the remaining V H and V L genes (Fig. 4) were translated and compared to the peptide sequencing results of the protein A-purified BBM.1 antibody.
Three different peptide chains were detected by Nterminal degradation, where only two were expected for a pure monoclonal. The signal for one of the peptide chains was too weak to determine its sequence with a high level of confidence, while the two predominant peptide chains were found in approximately equal proportions. The sequence of the MOPC-21 j light chain was used to infer the sequence of the second peptide chain in the BBM.1 antibody sample. This peptide sequence matched the cloned V H sequence, but did not match that of the MOPC-21 heavy chain [38] . Meanwhile, the sequence of the cloned V L gene did not match the sequence of the MOPC-21 j light chain. These findings suggested that the cloned V H and V L genes belonged to the anti-b 2 -m antibody secreted by the BBM.1 hybridoma.
Display of scFv fragment by yeast
The Figure 6 gives the sequence of the secreted scFv fragment, while Figure 7 demonstrates the purity of the scFv fragment after purification by nickel affinity chromatography. One minor peak and two major peaks were eluted from the size-exclusion column (as resolved by monitoring the absorbance at 280 nm). The minor peak corresponded to the exclusion limit of the resin, while the two major peaks (approximately the same size) corresponded to the molecular weights of the scFv fragment and its dimer. The fractions from the two major peaks were pooled to improve the yield of scFv fragment preparation and used to produce the immunoadsorptive media.
Secretion of scFv fragment by yeast
ScFv dimer ScFv monomer
Non-reduced Reduced Fig. 7 . Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of the secreted BBM.1-single-chain variable region antibody fragments (scFv) fragment after nickel affinity purification. The reduced sample was treated with 5% betamercaptoethanol and boiled for 5 minutes to dissociate the scFv dimer.
The yield of purified scFv fragment per unit volume of culture was 1.5 mg/L.
Immunoadsorbent based on scFv fragment
The TCEP reducing gel increased the molar ratio of free thiol groups to scFv fragments from less than 0.1% to 50%. At the end of the immobilization reaction, 25% of the total, or 50% of the reduced scFv fragment, had bound to the Sulfo-SMCC-activated gel. This corresponds to an immobilization density of 2.4 ± 0.2 mg scFv/mL settled gel. No leaching of the scFv fragment from the immunoadsorbent was detected in the PBS rinses (SDS-PAGE), cysteine quenching buffer (SDS-PAGE), or in the neutralized stripping buffer (Western blot).
The observed b 2 -m adsorption site density (q s ) did not significantly depend on the b 2 -m concentration under saturating conditions, nor did it significantly change after one round of regeneration ( Table 1 ). The average measured value of q s was 0.41 ± 0.01 mg b 2 -m/mL settled gel, which corresponds to a binding activity of 42% (molar ratio of adsorbed b 2 -m to immobilized scFv fragment) for the immobilized scFv fragment. Under subsaturating conditions (C 0 = 15 mg/mL), the regenerated immunoadsorbent possessed sufficient affinity to bring the concentration down to C eq = 1.0 ± 0.1 mg/L (N = 5). The immunoprecipitation experiments with radiolabeled cell lysate from the human cell line U373-MG (astrocytoma cells) suggest a high degree of specificity of the immunoadsorbent toward soluble and complexed (with the heavy chain of MHC I) b 2 -m (Fig. 8) .
DISCUSSION
The removal of b 2 -m from human blood plasma has previously been investigated with immunoadsorbents consisting of whole anti-b 2 -m antibodies immobilized onto porous beads [39] [40] [41] [42] . These small-scale affinity chromatography experiments have demonstrated that an immunoadsorbent can remove b 2 -m from human plasma with an affinity that has not been achieved with hydrophobic interaction-based adsorbents [6, 7] . Furthermore, these antibody-based adsorbents were found to be highly specific for b 2 -m, while the specificity of hydrophobic interaction-based adsorbents continues to be a concern [8, 10] . To date, perhaps the most promising antib 2 -m immunoadsorbent has been reported by Vallar et al [41] , which consisted of monoclonal antibodies immobilized onto Sepharose CL-4B gel beads. This adsorbent was highly regenerable and possessed a b 2 -m adsorption site density (0.9 mg b 2 -m/mL settled gel) that is expected to be sufficient, but not optimal for actual clinical application (i.e., 350 mL settled volume of adsorbent required to remove 315 mg of b 2 -m).
While the results of these preliminary investigations are encouraging, the challenge of removing b 2 -m from whole blood in a single extracorporeal device has not been addressed until recently [16] . More specifically, we have successfully removed low concentrations of b 2 -m (3.2 mg/L) from whole human blood in vitro at a therapeutically relevant flow rate (200 mL blood/min) using a novel, plasmapheretic extracorporeal device (the VFPR) and an immunoadsorbent based on whole BBM.1 antibodies. The concentration of b 2 -m that was cleared by the VFPR device was limited by a low b 2 -m adsorption site density (q s = 0.030 ± 0.002 mg b 2 -m/mL settled gel), which was caused by the low molar binding activity of the immobilized BBM.1 antibody (only 6% of the immobilized antibody-bound b 2 -m). Nevertheless, the immobilized whole antibodies (BBM.1) that retained binding activity demonstrated a high affinity for b 2 -m (K D = 0.1 ± 0.1 mg/L) as well as the ability to be regenerated repeatedly (>10×) without a detectable loss of binding activity. At the time, we hypothesized that the low b 2 -m adsorption site density was either caused by the excessive deactivation of the monoclonal antibody by the immobilization chemistry (cyanogen bromide activation of agarose) and/or the expression of an additional, unwanted immunoglobulin chain (impurity) by the hybridoma cell line.
Research into the origin of the BBM.1 antibodyproducing hybridoma cell line (HB-28) has revealed that it was created using the X63-Ag8 myeloma [15] , which has been shown to secrete the MOPC-21 j light and IgG1 heavy chains [23, 38] . In light of this fact, protein A-purified BBM.1 antibody was partially sequenced through N-terminal degradation. The results suggest that the protein sample primarily consisted of the MOPC-21 light chain and an IgG heavy chain other than the MOPC-21 IgG1 chain (presumably the anti-b 2 -m heavy chain), with a trace amount (<10%) of a third peptide chain Mean mg b 2 -m/mL settled gel 0.41 ± 0.01 Significance (adsorption site density before and after regeneration) P > 0.2
Various initial concentrations (C 0 ) of b 2 -m AF488 were equilibrated with 10 lL volumes of the immunoadsorptive media (V gel ) in 0.400 mL fetal calf serum (FCS) phosphate-buffered saline (PBS) (V total ) at 37
• C for 1 hour. The equilibrium concentration of desorbed b 2 -m AF488 (C eq ) was measured and used to calculate the b 2 -m adsorption site density (q s ) using equation 6 . These experiments were conducted on the immunoadsorptive media before and after regeneration with 0.3 mol/L glycine, pH 2. (presumably the anti-b 2 -m light chain). The apparent absence of MOPC-21 IgG1 in the protein sample can be explained by the fact that protein A is known to bind to IgG2b with a higher affinity than IgG1 [43] and that the BBM.1 antibody has been classified as IgG2b [15] . The optimization of an immunoadsorbent for the extracorporeal removal of b 2 -m will require the maximization of the b 2 -m adsorption site density to minimize the required volume of immunoadsorbent. The volume of immunoadsorbent contained within the extracorporeal device is an important parameter for the optimization of biocompatibility, as it is proportional to the amount of blood plasma retained during therapeutic operation. One strategy for achieving higher b 2 -m adsorption site densities is to use scFv antibody fragments as immunoadsorption ligands instead of significantly larger whole antibodies (1 mg of scFv fragment can bind 0.4 mg of b 2 -m, whereas 1 mg of whole antibody can only bind 0.16 mg of b 2 -m). Another advantage of scFv fragments over whole antibodies is their ability to be expressed by microbial vectors. This makes scFv fragments amenable to in vitro evolution in a convenient yeast display format and provides more options for process optimization, potentially resulting in a significant reduction in production cost. ScFv fragments are also genetically defined, which offers the opportunity to eliminate the expression of unwanted peptide chains by the source hybridoma cell line.
Motivated by the potential advantages of scFv fragments, the desirable affinity and regeneration capacity of BBM.1, and the apparent MOPC-21 j light chain contamination, we created an immunoadsorbent for the removal of b 2 -m that is based on BBM.1 scFv fragments. The BBM.1 scFv was first expressed in a yeast display format to facilitate the characterization of its phenotype and to enable the engineering of its properties (i.e., stability and/or regeneration capacity under various conditions) through in vitro evolution, if it is desired in the future.
The binding affinity of the yeast-displayed scFv fragment for b 2 -m was quantitated by FACS analysis. The measured value of K D (0.7 ± 0.3 nmol/L = 0.008 ± 0.004 mg/L) is in agreement with that previously reported for the agarose-immobilized whole BBM.1 antibody (0.1 ± 0.1 mg/L) [44] . This result is noteworthy from an antibody engineering perspective, because the conversion of a whole antibody to a wild-type scFv fragment can result in a significant decrease in affinity [45] . Furthermore, our reported value for K D is well below the b 2 -m concentration range expected in the blood plasma of healthy individuals (1.0 to 3.0 mg/L) [14] . Hence, the yeast-displayed wild-type BBM.1 scFv fragment possesses an affinity for recombinant human b 2 -m that is optimal for the clinical treatment of DRA through extracorporeal immunoadsorption.
Given the encouraging binding affinity of the yeastdisplayed antibody fragment, the scFv gene (a Kex2 protease-resistant version) was expressed by a yeast secretion vector. The selected protein expression and purification methods produced enough of the scFv fragment so that a small volume of a model scFv immunoadsorbent could be produced for investigational purposes. The molar binding activity (42%) and the b 2 -m adsorption site density (q s = 0.41 ± 0.01 mg b 2 -m/mL settled gel) of the scFv-based adsorbent are significantly greater than those measured for the whole BBM.1 antibody-based adsorbent (molar binding activity of 6%, q s = 0.030 ± 0.002 mg b 2 -m/mL settled gel). This improvement can be attributed to the elimination of the production of the MOPC-21 light chain by the cloning procedure. Hence, this work demonstrates how the creation of a wild-type scFv fragment from an existing hybridoma cell line can be used to separate desired antibody genes from contaminating ones. Under saturating conditions (C eq K D ), the mass ratio of adsorbed b 2 -m to immobilized antibody (0.17 ± 0.02 mg b 2 -m/mg scFv) is roughly equivalent to the theoretical limit for 100% active, bivalent whole IgG antibody (0.16 mg b 2 -m/mg antibody) and 70% higher than that actually achieved by Vallar et al [41] (0.1 mg b 2 -m/mg antibody). Shabunina, Afanas'eva, and Pokrovskii [42] have immobilized whole, polyclonal anti-b 2 -m antibodies onto Sepharose CL-4B at densities that range from 2 to 16 mg/mL settled gel. Over this range the mass ratio of adsorbed b 2 -m to immobilized antibody remained constant (0.04 mg b 2 -m/mg antibody). If this immobilization density can be achieved for the BBM.1 scFv while maintaining a molar binding activity of 42%, a new immunoadsorbent with a b 2 -m adsorption site density of 2.7 mg b 2 -m/mL settled gel could theoretically be produced. This would represent a threefold increase over the b 2 -m adsorption site density reported by Vallar and co-workers [41] , which is the highest reliable value reported in the literature. Mogi et al [39] reported a b 2 -m adsorption site density of 4.3 mg/mL. However, this value is not reliable because their reported antibody immobilization density (18.8 mg antibody/mL gel) corresponds to a mass ratio of adsorbed b 2 -m to immobilized antibody (0.23 mg b 2 -m/mg antibody) that is well above the theoretic limit (0.16 mg b 2 -m/mg antibody). In the present work, we also investigated the specificity of the agarose-immobilized scFv in vitro, as this property is important for clinical application. The introduction of specific protein clearance to dialysis therapies via scFvs would eliminate the loss of middle molecular weight proteins that are important to the patient. It would also allow specific removal of large proteins (>40 kD) that are suspected to mediate or cause disease but cannot be removed via conventional size exclusion-based methods. Specificity of the immunoadsorbent should be ultimately evaluated during perfusion of human blood; nevertheless, we can obtain some insight into this property through immunoprecipitation of b 2 -m from the lysate of astrocytoma cells. This human cell line is commonly used in studies investigating the MHC I complex. These cells secrete b 2 -m (along with hundreds of other human proteins) and also express MHC I on the cell surface. As expected, our results showed that non-specific binding to the immunoadsorbent was insignificant.
The presence of the heavy chain band in Figure 8 suggests that the fragment was able to recognize free monomeric, soluble b 2 -m as well as b 2 -m bound to the heavy chain of the MHC I complex. This coprecipitation of the heavy chain was also observed with the positive control; the hybridoma-produced monoclonal antibody BBM.1 (which has been shown to bind free and MHC I-bound b 2 -m with similar affinity [15] ). This finding is not unexpected as BBM.1 monoclonal antibody was originally a product from the immunization of mice with cells expressing human MHC I. Furthermore, the antigenic epitopes on b 2 -m are not involved in MHC I heavy chain interactions [15, 46] . The ability of our scFv to bind soluble as well as MHC I-bound b 2 -m suggests that it recognizes the same epitopes as its parent antibody, BBM.1 (epitopes that are normally exposed). This particular recognition ability has interesting implications for the removal of nonglycosylated "amyloidogenic" forms of b 2 -m from blood (such as partly denatured or destabilized monomeric b 2 -m species in solution, which have been shown to have a higher propensity to fibril formation relative to the properly folded protein [47] [48] [49] [50] [51] [52] ). Recent publications regarding the amyloidogenic potential of monomeric b 2 -m suggest that the epitope recognized by BBM.1 remains in its native-like configuration despite a global partially folded state in solution [50, 53, 54] . (BBM.1 as well as the scFv can bind b 2 -m that is properly folded as well as denatured via SDS, data not shown). Partly denatured forms of b 2 -m, although a small percentage of total b 2 -m in solution (∼14%), may one day prove to be important targets to delay amyloid formation [50, 51, 54, 55] .
To the best of our knowledge, this is the first time that a scFv-based adsorbent for the extracorporeal removal of b 2 -m has been reported. Under saturating conditions, this new type of immunoadsorbent binds a mass ratio of adsorbed b 2 -m to immobilized antibody that is above the theoretic limit obtainable with whole antibodies. Future work will involve the optimization of the scFv fragment expression, purification, and immobilization methods. Larger volumes (100 to 200 mL) of this scFv-based immunoadsorbent will be produced and used within a VFPR device to remove pathologic levels (20 to 60 mg/L) of b 2 -m from human blood. We expect that the immobilization density of the scFv fragment can be increased sufficiently such that, when combined with the high mass ratio of adsorbed b 2 -m to immobilized antibody, a b 2 -m adsorption site density can be achieved that is significantly greater than the highest reported to date (q s = 0.9 mg b 2 -m/mL settled gel [41] ). This increase in the b 2 m-adsorption site density should translate into a corresponding decrease in the volume of adsorbent needed for the proposed extracorporeal therapy, thereby improving the biocompatibility of the device. Future work for the implementation of this technology will also include the development of a comprehensive mathematical model for b 2 -m clearance from ESRD patients. This model, which should incorporate endogenous [56] [57] [58] [59] and extracorporeal [44] b 2 -m mass transfer phenomena, would give some insight into the long-term reduction rates that could potentially be observed in patients.
